Cargando…

Genetic platelet depletion is superior in platelet transfusion compared to current models

Genetically modified mice have advanced our knowledge on platelets in hemostasis and beyond tremendously. However, mouse models harbor certain limitations, including availability of platelet specific transgenic strains, and off-target effects on other cell types. Transfusion of genetically modified...

Descripción completa

Detalles Bibliográficos
Autores principales: Salzmann, Manuel, Schrottmaier, Waltraud C., Kral-Pointner, Julia B., Mussbacher, Marion, Volz, Julia, Hoesel, Bastian, Moser, Bernhard, Bleichert, Sonja, Morava, Susanne, Nieswandt, Bernhard, Schmid, Johannes A., Assinger, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271594/
https://www.ncbi.nlm.nih.gov/pubmed/31537686
http://dx.doi.org/10.3324/haematol.2019.222448
_version_ 1783542119777959936
author Salzmann, Manuel
Schrottmaier, Waltraud C.
Kral-Pointner, Julia B.
Mussbacher, Marion
Volz, Julia
Hoesel, Bastian
Moser, Bernhard
Bleichert, Sonja
Morava, Susanne
Nieswandt, Bernhard
Schmid, Johannes A.
Assinger, Alice
author_facet Salzmann, Manuel
Schrottmaier, Waltraud C.
Kral-Pointner, Julia B.
Mussbacher, Marion
Volz, Julia
Hoesel, Bastian
Moser, Bernhard
Bleichert, Sonja
Morava, Susanne
Nieswandt, Bernhard
Schmid, Johannes A.
Assinger, Alice
author_sort Salzmann, Manuel
collection PubMed
description Genetically modified mice have advanced our knowledge on platelets in hemostasis and beyond tremendously. However, mouse models harbor certain limitations, including availability of platelet specific transgenic strains, and off-target effects on other cell types. Transfusion of genetically modified platelets into thrombocytopenic mice circumvents these problems. Additionally, ex vivo treatment of platelets prior to transfusion eliminates putative side effects on other cell types. Thrombocytopenia is commonly induced by administration of anti-platelet antibodies, which opsonize platelets to cause rapid clearance. However, antibodies do not differentiate between endogenous or exogenous platelets, impeding transfusion efficacy. In contrast, genetic depletion with the inducible diphtheria toxin receptor (iDTR) system induces thrombocytopenia via megakaryocyte ablation without direct effects on circulating platelets. We compared the iDTR system with antibody-based depletion methods regarding their utility in platelet transfusion experiments, outlining advantages and disadvantages of both approaches. Antibodies led to thrombocytopenia within two hours and allowed the dose-dependent adjustment of the platelet count. The iDTR model caused complete thrombocytopenia within four days, which could be sustained for up to 11 days. Neither platelet depletion approach caused platelet activation. Only the iDTR model allowed efficient platelet transfusion by keeping endogenous platelet levels low and maintaining exogenous platelet levels over longer time periods, thus providing clear advantages over antibody-based methods. Transfused platelets were fully functional in vivo, and our model allowed examination of transgenic platelets. Using donor platelets from already available genetically modified mice or ex vivo treated platelets, may decrease the necessity of platelet-specific mouse strains, diminishing off-target effects and thereby reducing animal numbers.
format Online
Article
Text
id pubmed-7271594
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-72715942020-06-12 Genetic platelet depletion is superior in platelet transfusion compared to current models Salzmann, Manuel Schrottmaier, Waltraud C. Kral-Pointner, Julia B. Mussbacher, Marion Volz, Julia Hoesel, Bastian Moser, Bernhard Bleichert, Sonja Morava, Susanne Nieswandt, Bernhard Schmid, Johannes A. Assinger, Alice Haematologica Articles Genetically modified mice have advanced our knowledge on platelets in hemostasis and beyond tremendously. However, mouse models harbor certain limitations, including availability of platelet specific transgenic strains, and off-target effects on other cell types. Transfusion of genetically modified platelets into thrombocytopenic mice circumvents these problems. Additionally, ex vivo treatment of platelets prior to transfusion eliminates putative side effects on other cell types. Thrombocytopenia is commonly induced by administration of anti-platelet antibodies, which opsonize platelets to cause rapid clearance. However, antibodies do not differentiate between endogenous or exogenous platelets, impeding transfusion efficacy. In contrast, genetic depletion with the inducible diphtheria toxin receptor (iDTR) system induces thrombocytopenia via megakaryocyte ablation without direct effects on circulating platelets. We compared the iDTR system with antibody-based depletion methods regarding their utility in platelet transfusion experiments, outlining advantages and disadvantages of both approaches. Antibodies led to thrombocytopenia within two hours and allowed the dose-dependent adjustment of the platelet count. The iDTR model caused complete thrombocytopenia within four days, which could be sustained for up to 11 days. Neither platelet depletion approach caused platelet activation. Only the iDTR model allowed efficient platelet transfusion by keeping endogenous platelet levels low and maintaining exogenous platelet levels over longer time periods, thus providing clear advantages over antibody-based methods. Transfused platelets were fully functional in vivo, and our model allowed examination of transgenic platelets. Using donor platelets from already available genetically modified mice or ex vivo treated platelets, may decrease the necessity of platelet-specific mouse strains, diminishing off-target effects and thereby reducing animal numbers. Ferrata Storti Foundation 2020-06 /pmc/articles/PMC7271594/ /pubmed/31537686 http://dx.doi.org/10.3324/haematol.2019.222448 Text en Copyright© 2020 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Articles
Salzmann, Manuel
Schrottmaier, Waltraud C.
Kral-Pointner, Julia B.
Mussbacher, Marion
Volz, Julia
Hoesel, Bastian
Moser, Bernhard
Bleichert, Sonja
Morava, Susanne
Nieswandt, Bernhard
Schmid, Johannes A.
Assinger, Alice
Genetic platelet depletion is superior in platelet transfusion compared to current models
title Genetic platelet depletion is superior in platelet transfusion compared to current models
title_full Genetic platelet depletion is superior in platelet transfusion compared to current models
title_fullStr Genetic platelet depletion is superior in platelet transfusion compared to current models
title_full_unstemmed Genetic platelet depletion is superior in platelet transfusion compared to current models
title_short Genetic platelet depletion is superior in platelet transfusion compared to current models
title_sort genetic platelet depletion is superior in platelet transfusion compared to current models
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271594/
https://www.ncbi.nlm.nih.gov/pubmed/31537686
http://dx.doi.org/10.3324/haematol.2019.222448
work_keys_str_mv AT salzmannmanuel geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT schrottmaierwaltraudc geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT kralpointnerjuliab geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT mussbachermarion geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT volzjulia geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT hoeselbastian geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT moserbernhard geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT bleichertsonja geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT moravasusanne geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT nieswandtbernhard geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT schmidjohannesa geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels
AT assingeralice geneticplateletdepletionissuperiorinplatelettransfusioncomparedtocurrentmodels